VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener

Madrigal Pharmaceuticals, Inc. (MDGL) Total Return Calculator with Dividends Reinvested

Madrigal Pharmaceuticals, Inc.

Popular:

The total return for Madrigal Pharmaceuticals, Inc. (MDGL) stock is +64.00% over the past 12 months. So far it's down 15.39% this year. The 5-year total return is +287.83%, meaning $10,000 invested in MDGL stock 5 years ago would be worth $38,783 today. Total return includes price appreciation plus reinvesting any dividends paid out.

If you invested $10,000 in MDGL 1 year ago, it would be worth $18,288 today — you'd have gained $8,288.

With Dividends Reinvested$18,288+82.88%

Price Only (No DRIP)$18,288+82.88%

Period2025-05-06 → 2026-05-06

Price

Total Return (DRIP)

S&P 500

If You Invested $10,000 in MDGL

1Y$16,400+$6,400 (+64.0%)64.0% CAGR

3Y$16,401+$6,401 (+64.0%)17.9% CAGR

5Y$38,783+$28,783 (+287.8%)31.1% CAGR

10Y$368,109+$358,109 (+3581.1%)43.4% CAGR

15Y$25,142+$15,142 (+151.4%)6.3% CAGR

20Y$15,794+$5,794 (+57.9%)2.3% CAGR

30Y$15,793+$5,793 (+57.9%)1.5% CAGR

Madrigal Pharmaceuticals, Inc. did not pay dividends during this period. Total return = price return.

Loading MDGL total return...

As of 2026-05-06

Returns at a Glance

Period	Total Return	CAGR	Price Only	Div. Contrib.	$10K →
YTD	-15.39%	—	-15.39%	—	$8,461
1Y	+64.00%	64.00%	+64.00%	—	$16,400
3Y	+64.01%	17.93%	+64.01%	—	$16,401
5Y	+287.83%	31.14%	+287.83%	—	$38,783
10Y	+3581.09%	43.42%	+3581.09%	—	$368,109
15Y	+151.42%	6.34%	+151.42%	—	$25,142
20Y	+57.94%	2.31%	+57.94%	—	$15,794
30Y	+57.93%	1.54%	+57.93%	—	$15,793

Risk & Highlights

Best Year+475.13%2017

Worst Year-87.80%2015

Max Drawdown-29.36%2025-12-22 → 2026-03-03

Annual Returns

Year	Total Return	Price Return	Div.	S&P 500	vs S&P
2026YTD	-27.26%	-27.26%	—	+0.41%	-27.7pp
2025	+85.59%	+85.59%	—	+16.64%	+68.9pp
2024	+36.02%	+36.02%	—	+24.00%	+12.0pp
2023	-18.93%	-18.93%	—	+24.81%	-43.7pp
2022	+222.07%	+222.07%	—	-19.95%	+242.0pp

MDGL outperformed the S&P 500 by 35.56pp over the past year (+64.00% vs +28.44%).

Loading summary...

MDGL Peers' Total Return

Accurate peer set · 10 comparable names

Name	Mkt Cap	30D Rtn	YTD Total Rtn	1Y Total Rtn	Div Contrib	3Y Total Rtn	5Y Total Rtn	10Y Total Rtn
MDGLMadrigal Pharmaceuticals, Inc.	$11.4B	-5.9%	-15.4%	+64.0%	—	+64.0%	+287.8%	+3581.1%
AKROAkero Therapeutics, Inc.	$4.5B	—	—	+21.7%	—	+21.1%	+103.0%	+198.3%
HIMSHims & Hers Health, Inc.	$6.8B	+29.5%	-21.2%	-37.1%	—	+118.7%	+129.4%	+168.7%
ELVNEnliven Therapeutics, Inc.	$2.5B	+6.8%	+167.6%	+103.9%	—	+111.7%	+43.2%	-30.7%
TERNTerns Pharmaceuticals, Inc.	$4.6B	+0.4%	+32.1%	+1505.1%	—	+325.1%	+210.7%	+188.0%
GPCRStructure Therapeutics Inc.	$2.4B	-20.6%	-39.7%	+49.2%	—	+73.8%	+58.1%	+58.1%
NVCRNovoCure Limited	$1.8B	+50.5%	+21.0%	-10.6%	—	-76.7%	-92.1%	+40.0%
HALOHalozyme Therapeutics, Inc.	$7.8B	+4.4%	-6.3%	+8.7%	—	+112.5%	+37.8%	+584.0%
ARWRArrowhead Pharmaceuticals, Inc.	$10.5B	+22.6%	+10.5%	+436.0%	—	+81.1%	+12.7%	+1221.5%
ALNYAlnylam Pharmaceuticals, Inc.	$40.2B	-8.8%	-24.8%	+10.1%	—	+42.0%	+127.0%	+412.7%
VKTXViking Therapeutics, Inc.	$3.6B	-7.7%	-11.6%	+6.2%	—	+37.0%	+427.1%	+2404.8%

Compare:MDGL vs AKRO MDGL vs HIMS MDGL vs ELVN MDGL vs AKRO vs HIMS

About MDGL Dividend Returns

Madrigal Pharmaceuticals, Inc. (MDGL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of MDGL over the past year?

Madrigal Pharmaceuticals, Inc. (MDGL) delivered a return of 64.00% over the past year. Since MDGL does not currently pay dividends, the total return equals the price-only return.

Q2How much would $10,000 invested in MDGL be worth today?

A $10,000 investment in Madrigal Pharmaceuticals, Inc. one year ago would be worth $16,400 today, representing a gain of $6,400.

Q3Does MDGL pay dividends?

Madrigal Pharmaceuticals, Inc. (MDGL) does not currently pay dividends. Many growth-focused companies reinvest profits back into the business rather than distributing them as dividends. For MDGL, the total return equals the price-only return.

Q4Did MDGL beat the S&P 500?

Yes, Madrigal Pharmaceuticals, Inc. (MDGL) outperformed the S&P 500 by 35.56 percentage points over the past year. MDGL delivered a total return of 64.00%, compared to the S&P 500's 28.44%. This 35.56pp alpha means investors in MDGL earned more than a passive S&P 500 index fund.

Q5What is MDGL's worst drawdown?

Madrigal Pharmaceuticals, Inc. (MDGL) experienced a maximum drawdown of -29.36% over the past year, declining from its peak on 2025-12-22 to its trough on 2026-03-03. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is MDGL's long-term total return over 10, 20, or 30 years?

Here are Madrigal Pharmaceuticals, Inc. (MDGL)'s long-term returns with dividends reinvested. Over 10 years, the total return is 3581.1% (43.4% CAGR) — $10,000 would have grown to $368,109. Over 20 years: 57.9% total return (2.3% CAGR) — $10,000 → $15,794. Over 30 years: 57.9% total return (1.5% CAGR) — $10,000 → $15,793. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was MDGL's best and worst year?

Madrigal Pharmaceuticals, Inc.'s best calendar year was 2017 with a total return of 475.1%. Its worst year was 2015 with a total return of -87.8%. This range shows the volatility investors should expect — the difference between the best and worst year is 562.9 percentage points.